PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer

The goal of this clinical trial is to learn if adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can control cancer longer in adults with high-risk advanced hepatocellular carcinoma (liver cancer). It will also learn about the safety of this combination. The main questions it aims to answer are: * What percentage of participants are alive without cancer progression 12 months after starting PULSAR? * What medical problems do participants have after PULSAR with immunotherapy? There is no comparison group. Results will be compared with published results

Trial Details

NCT ID

NCT07884877

Phase

PHASE2

Sponsor

Samsung Medical Center

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy)
Immune checkpoint inhibitor-based therapy

Locations (sample)

Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

Age 19 years or older
Hepatocellular carcinoma diagnosed histologically or clinically according to the Korean Liver Cancer Association-National Cancer Center guidelines
Unresectable and/or locally advanced or metastatic disease, currently receiving or scheduled to receive immune checkpoint inhibitor-based systemic …
At least one of the following high-risk features:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →